Recent advances of novel targeted therapy for squamous cell carcinoma of the head and neck

Bibliographic Details
Title: Recent advances of novel targeted therapy for squamous cell carcinoma of the head and neck
Authors: Jed A. Katzel, Michael P. Fanucchi, William A. Cook, Zujun Li
Source: Oncology Reviews, Vol 3, Iss 3 (2011)
Publisher Information: Frontiers Media S.A., 2011.
Publication Year: 2011
Collection: LCC:Other systems of medicine
LCC:Internal medicine
Subject Terms: Epidermal growth factor receptor - Cetuximab - Vascular endothelial growth factor receptor - Head and neck cancer - Targeted therapy, Other systems of medicine, RZ201-999, Internal medicine, RC31-1245
More Details: Targeted therapies have proven beneficial for patients suffering from a number of different malignancies, including cancers of the head and neck. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor has shown benefit in combination with radiation for untreated patients or as a single agent for patients with platinum resistant disease. Cetuximab is the only targeted agent currently approved by the Federal Drug Administration for the treatment of head and neck cancer. A number of other agents have shown promising initial results including intracellular tyrosine kinase inhibitors, agents targeting vascular endothelial growth factor receptor, as well as other classes of novel therapies. Some of the data supporting the use of targeted therapy, including agents not yet approved in head and neck cancer, will be presented in this review. As our understanding of the cancer cell signaling pathways and novel targeted agents increases, the potential for treatment with reduced toxicity and improved clinical outcomes will become a reality.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1970-5557
1970-5565
Relation: http://www.oncologyreviews.org/index.php/or/article/view/89; https://doaj.org/toc/1970-5557; https://doaj.org/toc/1970-5565
DOI: 10.4081/oncol.2009.149
Access URL: https://doaj.org/article/d43fdd497acf46feaf35f93160ef9248
Accession Number: edsdoj.43fdd497acf46feaf35f93160ef9248
Database: Directory of Open Access Journals
More Details
ISSN:19705557
19705565
DOI:10.4081/oncol.2009.149
Published in:Oncology Reviews
Language:English